| pubmed-article:17070146 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C1956346 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0010068 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C1277187 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0242698 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0439133 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C0257190 | lld:lifeskim |
| pubmed-article:17070146 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:17070146 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17070146 | pubmed:dateCreated | 2006-10-30 | lld:pubmed |
| pubmed-article:17070146 | pubmed:abstractText | Raised resting heart rate (HR) is associated with increased cardiovascular and total mortality. Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina. Because patients with coronary artery disease and left ventricular dysfunction are at high risk of cardiac events and death, we hypothesized that they could derive particular benefit from a specific HR-lowering agent such as ivabradine. | lld:pubmed |
| pubmed-article:17070146 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17070146 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17070146 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17070146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17070146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17070146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17070146 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17070146 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17070146 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:GenM CMC | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:FordIanI | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:StegPhilippe... | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:FerrariRobert... | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:TenderaMichal... | lld:pubmed |
| pubmed-article:17070146 | pubmed:author | pubmed-author:BEAUTIFUL... | lld:pubmed |
| pubmed-article:17070146 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17070146 | pubmed:volume | 152 | lld:pubmed |
| pubmed-article:17070146 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17070146 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17070146 | pubmed:pagination | 860-6 | lld:pubmed |
| pubmed-article:17070146 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:meshHeading | pubmed-meshheading:17070146... | lld:pubmed |
| pubmed-article:17070146 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17070146 | pubmed:articleTitle | Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. | lld:pubmed |
| pubmed-article:17070146 | pubmed:affiliation | Royal Brompton Hospital, Sydney Street, London, UK. | lld:pubmed |
| pubmed-article:17070146 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17070146 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17070146 | lld:pubmed |
